DCF Studio

    PME.AX · ASX · Healthcare

    Pro Medicus Limited

    Also onShortfallConsensus DriftCrosscheck

    Implied value per share

    AUD 50.15

    Market price

    AUD 169.57

    Implied upside

    -70.4%

    5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case

    AdjustedSome line items were not reported and have been derived. Each one is labelled in the workings below.

    Current EV/EBITDA of 85.6x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.

    Value Per Share

    Perpetuity growth
    AUD 50.15-70.4%
    Exit multiple
    AUD 97.81-42.3%
    Market price
    AUD 169.57

    Same forecast, different terminal treatment. Percentages vs price.

    Forecast Cashflows

    Reporting currency (AUD). Outflows negative.

    0m197m393mFY27FY28FY29FY30FY31
    Nominal FCFFDiscounted to todayAUD
    LineFY27FY28FY29FY30FY31CAGR
    RevenueAUD 334.8mAUD 428.5mAUD 548.5mAUD 702.0mAUD 898.4m+28.0%
    EBITAUD 239.1mAUD 306.0mAUD 391.6mAUD 501.2mAUD 641.4m+28.0%
    NOPATAUD 168.5mAUD 215.7mAUD 276.0mAUD 353.3mAUD 452.1m+28.0%
    Add depreciation & amortisationAUD 15.2mAUD 19.4mAUD 24.8mAUD 31.8mAUD 40.7m+28.0%
    Less capital expenditureAUD -13.5mAUD -17.2mAUD -22.1mAUD -28.2mAUD -36.2m+28.0%
    Less increase in working capitalAUD -23.5mAUD -30.1mAUD -38.5mAUD -49.3mAUD -63.1m+28.0%
    Free cashflow to firmAUD 146.6mAUD 187.7mAUD 240.2mAUD 307.4mAUD 393.5m+28.0%
    Discount factor0.95490.87080.79410.72420.6604-
    Present valueAUD 140.0mAUD 163.4mAUD 190.8mAUD 222.6mAUD 259.9m+16.7%
    Present Value Of The ForecastAUD 976.7m

    Discount Rate

    Source shown per component. All overridable above.

    Risk-free rate5.35%Australian Government 10-year (RBA F2)
    Equity risk premium6.00%Market assumption
    Beta0.719Reported 0.580, pulled toward 1.0 (Blume)
    Cost of equity9.66%Risk-free + beta x equity risk premium
    Cost of debt7.35%Assumed: risk-free + 2bp (interest expense not reported)
    Market capitalisationAUD 17.7bn100.0% of capital
    Total debtAUD 2.2m0.0% of capital, book value as a proxy
    Tax rate29.5%Effective, capped at statutory
    WACC9.66%E/V x Re + D/V x Rd x (1 - t)

    Terminal Value

    Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.

    Perpetuity growth at 2.50%

    Value per shareAUD 50.15

    80% of EV

    Forecast FCFF, final year
    AUD 393.5m
    Capex at depreciation, working capital in reinvestment
    AUD 452.1m
    Less reinvestment at g/ROIC (5.9% of NOPAT)
    AUD -26.7m
    Capitalised
    AUD 425.4m
    ROIC (reported)
    42.3%
    Terminal value, undiscounted
    AUD 6.1bn
    Terminal value, discounted
    AUD 4.0bn
    Enterprise value
    AUD 5.0bn
    Less net debt
    AUD -248.4m
    Equity value
    AUD 5.2bn

    Exit at 20.0x EBITDA

    Value per shareAUD 97.81

    90% of EV

    Terminal value, undiscounted
    AUD 13.6bn
    Terminal value, discounted
    AUD 9.0bn
    Enterprise value
    AUD 10.0bn
    Less net debt
    AUD -248.4m
    Equity value
    AUD 10.2bn

    Spread between methods: 64%.

    Sensitivity

    Value per share (AUD) by discount rate and long-run growth.

    Long-run growth
    Discount rate1.50%2.00%2.50%3.00%3.50%
    7.66%61.4865.4470.1675.8882.97
    8.66%52.6255.3558.5262.2466.68
    9.66%45.9547.9250.1552.7255.70
    10.66%40.7642.2243.8645.7047.80
    11.66%36.6037.7238.9540.3241.86

    Outlined: this model. Green text: above today's price of 169.57. Shading: distance from this model's own value.

    Priced In

    What each input would have to be to justify the current price, one at a time.

    InputModelImpliedGap
    Revenue growth, every year28.0%67.2%+39.2pp
    Discount rate9.7%4.7%-5.0pp
    Download as Excel

    Live formulas, not pasted numbers - edit a driver and the workbook reprices.

    Yahoo Finance and RBA data. General information, not advice. Methodology.